SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 13, 2026 - P2 | N=47 | Recruiting | Sponsor: Shandong Cancer Hospital and Institute | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor
|